Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Murine N4 Ube3am-/p+ hippocampus: Antagomir-134 vs Scramble (control)

ABSTRACT: Murine N4 Ube3am-/p+ hippocampus: Antagomir-134 vs Scramble (control)

PROVIDER: PRJNA819106 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18458316_1.fastq.gz	Fastqsanger.gz
	SRR18458316_2.fastq.gz	Fastqsanger.gz
	SRR18458317_1.fastq.gz	Fastqsanger.gz
	SRR18458317_2.fastq.gz	Fastqsanger.gz
	SRR18458318_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Murine N4 Ube3am-/p+ hippocampus: Antagomir-134 vs Scramble (control)

Project description:Transcriptional profiling of N4 Ube3am-/p+ mice ipsilateral hippocampi at 24h after the last audiogenic stimulus (at postnatal day 27; out of three stimulus) of mice pre-treated with either scramble or antagomir-134 (Ant-134; 0.5 nmol; ICV).

2023-03-13 | GSE199276 | GEO

Murine hippocampus: Scramble (control) vs Antagomir-134

Project description:Murine hippocampus: Scramble (control) vs Antagomir-134

| PRJNA699257 | ENA

Murine hippocampus: Scramble (control) vs Antagomir-134

Project description:Transcriptional profiling of mouse ipsilateral hippocampi at 24 hours after intra-amygdala kainic acid-induced status epilepticus followed by either Antagomir-134 or Scramble (control) treatment (intraperitoneal; 30 mg.kg-1)

2021-02-04 | GSE166097 | GEO

miRNAs affected by antagomiR-17 treatment

Project description:To understand the the effect of antagomir-17 treatment on human endothelial cells derived from human umbilical cord blood (UCB) CD34+ hematopoietic stem cells, we have employed mRNA sequencing. The antagomiR-17 used in this study was purchased from Dharmacon and cell transfection was performed using Lipofectamine RNAiMAx from Life Technologies. Scramble antagomiR from Ambion was used as control. Cells were transfected with antagomiR-17 or scrambled antagomiR for 48 hours. After 48 h, the cells were collected, RNA was isolated and RNA samples were shipped to Exiqon Services, Denmark for mRNA sequencing. All sequencing experiments (RNA integrity measurements, library preparation and next generation sequencing) were conducted at Exiqon Services, Denmark.

2017-07-07 | GSE76663 | GEO

Perturbation of healthy iPSC-CM with hsa-miR-134, hsa--433, and hsa-487b mimic and inhibitor

Project description:In this study, healthy iPSC-CM were transfected with hsa-miR-134, hsa--433, and hsa-487b mimic and inhibitor to study their effects on human cardiac proliferation after it was found that these miRNAs were enriched in maternal blood plasma within SVHD pregnancies. Mock and scramble were used as controls. Overall, it was found that miR134 and miR487b influenced human iPSC-CM proliferation.

2024-10-02 | GSE266333 | GEO

Base-resolution detection of N4-methylcytosine in genomic DNA using 4mC-TAB-seq

Project description:N4-methylcytosine is a major DNA modification integral to restriction-modification (R-M) systems in bacterial genomes. Here we describe 4mC-Tet-Assisted Bisulfite-sequencing (4mC-TAB-seq), a method that accurately and rapidly reveals the genome-wide locations of N4-methylcytosines at single-base resolution. By coupling Tet-mediated oxidation with a modified sodium bisulfite conversion reaction, unmodified cytosines and 5-methylcytosines are read out as thymines, whereas N4-methylcytosines are read out as cytosines revealing their positions throughout the genome. 4mC-TAB-seq

2015-07-11 | E-GEOD-63371 | biostudies-arrayexpress

Ensifer sp. SEMIA 134 isolate:SEMIA 134

Project description:Ensifer sp. SEMIA 134 isolate:SEMIA 134 Genome sequencing and assembly

| PRJNA536634 | ENA

Sinorhizobium medicae strain:134

Project description:Sinorhizobium medicae 134 Resequencing

| PRJNA499354 | ENA

Preclinical characterization of antagomiR-218 as a potential treatment for Myotonic Dystrophy

Project description:Myotonic Dystrophy (DM1) is a rare neuromuscular disease caused by the expansion of unstable CTG repeats in a non-coding region of the DMPK gene. CUG expansions in mutant DMPK transcripts fold into hairpins that sequester MBNL1 proteins in ribonuclear foci, depletion of MBNL1 being a chief contribution to disease symptoms such as muscle weakness and atrophy, and myotonia. Thus, the upregulation of endogenous MBNL1 levels may compensate for the sequestration. We have demonstrated that antisense oligonucleotides against miR-218 boost expression of MBNL1 and rescue phenotypes in disease models. Here we provide a preclinical characterization of an antagomiR-218 molecule using the HSALR mouse model and patient-derived myoblasts. In HSALR, antagomiR-218 rescued molecular and functional phenotypes in a dose-dependent manner, showed a good toxicity profile, and lasted some 15 days after a single subcutaneous injection. In muscle tissue, the antagomiR rescued the normal subcellular distribution of Mbnl1 and did not alter the percentage of myonuclei containing CUG foci. In patient-derived cells, antagomiR-218 improved defective fusion and differentiation and rescued up to 34% of the gene expression alterations found in the transcriptome of patient myoblasts. Importantly, miR-218 was found upregulated in DM1 muscle biopsies, which makes this miRNA a relevant therapeutic target.

2021-01-31 | GSE158216 | GEO